SCHEMBL2484742

SCHEMBL2484742

COc1ccc(-c2cc(=O)c3c(OC)cc(OCC(=O)NS(=O)(=O)c4ccccc4)cc3o2)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.58
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 3/20 0.51
ABCG2 Q9UNQ0 3/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
HPGD P15428 3/20 0.49
POLB P06746 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
MAPT P10636 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ABL1 P00519 3/20 0.48
CYP1B1 Q16678 2/20 0.48
ABCB1 P08183 3/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2486820 0.88 PPARG (0.55) PPARGKDM4EALDH1A1ABCG2MEN1
SCHEMBL2486112 0.87 PPARG (0.56) PPARGKDM4EALDH1A1ABCG2MEN1
Recoflavone SCHEMBL7603767 0.84 ABCB1 (0.58) PPARGKDM4EALDH1A1ABCG2MEN1
Recoflavone SCHEMBL2483541 0.83 ABCB1 (0.59) PPARGKDM4EALDH1A1ABCG2MEN1
Recoflavone SCHEMBL29406117 0.83 ABCB1 (0.59) PPARGKDM4EALDH1A1ABCG2MEN1
SCHEMBL2482027 0.82 PPARG (0.57) PPARGKDM4EALDH1A1ABCG2MEN1
SCHEMBL2481948 0.82 PPARG (0.57) PPARGKDM4EALDH1A1ABCG2MEN1
Recoflavone SCHEMBL2483546 0.82 ABCB1 (0.58) PPARGKDM4EALDH1A1ABCG2MEN1
SCHEMBL14178905 0.82 ABCB1 (0.58) PPARGKDM4EALDH1A1ABCG2MEN1
SCHEMBL2482206 0.82 PPARG (0.56) PPARGKDM4EALDH1A1ABCG2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8203011-B2 3′,4′,5-trimethoxy flavone derivatives as stimulant of mucus secretion, method for the same, and pharmaceutical composition comprising the same DONG-A PHARM. CO., LTD. (KR) 2012-06-19 US claimed
EP-2170857-B1 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULANT OF MUCUS SECRETION, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONG A PHARM CO LTD (KR) 2011-10-19 EP claimed
US-20100130448-A1 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULATN OF MUCUS SECRETION, METHOD FOR THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONG-A PHARM. CO., LTD (KR) 2010-05-27 US claimed
EP-2170857-A2 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULANT OF MUCUS SECRETION, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Dong-A Pharm.Co., Ltd. (KR) 2010-04-07 EP claimed
WO-2008150085-A2 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULANT OF MUCUS SECRETION, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONG-A PHARM. CO., LTD. (KR) 2008-12-11 WO claimed
US-8203011-B2 3′,4′,5-trimethoxy flavone derivatives as stimulant of mucus secretion, method for the same, and pharmaceutical composition comprising the same DONG-A PHARM. CO., LTD. (KR) 2012-06-19 US disclosed
EP-2170857-B1 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULANT OF MUCUS SECRETION, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONG A PHARM CO LTD (KR) 2011-10-19 EP disclosed
US-20100130448-A1 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULATN OF MUCUS SECRETION, METHOD FOR THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONG-A PHARM. CO., LTD (KR) 2010-05-27 US disclosed
EP-2170857-A2 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULANT OF MUCUS SECRETION, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Dong-A Pharm.Co., Ltd. (KR) 2010-04-07 EP disclosed
WO-2008150085-A2 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULANT OF MUCUS SECRETION, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONG-A PHARM. CO., LTD. (KR) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130448-A1 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULATN OF MUCUS SECRETION, METHOD FOR THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME TLR5, PTN, TSLP PPARG 2853/4885KDM4E 2596/4885ALDH1A1 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.